• Genentech’s Hemlibra Maintains Strong Bleeding Control Results in Phase 3 Trial, Interim Analysis Shows
  • Joint Problems May Be Good Indicator of Low Bone Density and Osteoporosis
  • Mama Bears and Warriors: Tears and Joy
  • FDA Updates Label of Bioverativ’s Alprolix Upon Review of Positive Interim B-YOND Trial Data
  • Nuwiq Seen as Safe and Effective Pre-surgical Treatment for People with Severe Hemophilia A
  • HAVEN 3 Data Supports Use of Hemlibra to Treat Hemophilia A Patients Without Factor VIII Inhibitors
  • Hemophilia and the Holidays: Always Thankful
  • FDA Considers Restart of Trials with Fitusiran for Hemophilia A and B After Recent Setback
  • New Treatment for Hemophilic Joint Disease Granted Orphan Drug Status by FDA
  • Life-Changing News: Hope for Hemophilia A and Inhibitors
  • Rare Disease Patient Groups Unite to Preserve Orphan Drug Tax Credit in US
  • European Medicines Agency Recommends Adynovi’s Approval for Hemophilia A